Wells Fargo Raises argenx (ARGX) Price Target to $1,356
Wells Fargo has reaffirmed its Overweight rating on argenx SE, setting a price target of $1,356 on October 14, 2026, a 63.23% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wells Fargo raised its price target on argenx SE ($ARGX) to $1,356 from $1,355 on October 14, 2026, and rates the stock "Overweight".
Since the rating, $ARGX is up 0.1% to date (from the $818.30 close on Oct 14, 2026).
ARGX
argenx SE
Key Points
- On October 14, 2026, Wells Fargo reiterated its Overweight rating on argenx SE, adjusting its price target from $1,355 to $1,356.
- Wells Fargo's $1,356 price target implies 63.23% upside from argenx SE's ($ARGX) current $830.71 share price.
- As of October 16, 2026, argenx SE's stock was recently trading around $830.71, which is about 38.7% below the new price target.
- argenx SE has shown strong financial performance, reporting a revenue growth of 59.3% year-over-year.
Get $ARGX trade alerts by text
We text you when insiders, Congress or big funds trade $ARGX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
Wells Fargo has reaffirmed its Overweight rating on argenx SE (NasdaqGS: ARGX) and set a new price target of $1,356 on October 14, 2026. This change marks a slight increase from the previous target of $1,355.
Wells Fargo vs. the S&P 500
Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in argenx SE
Several institutional investors hold significant stakes in argenx SE. FMR, LLC increased its holdings by 240,561 shares, bringing its total to 5,231,452 shares valued at approximately $4.29 billion. Meanwhile, Jupiter Topco LLC saw a notable increase of 1,237,008 shares, ending with 2,474,015 shares worth around $2.03 billion. In contrast, Price (T.Rowe) Associates Inc reduced its position by 696,933 shares, now holding 2,678,047 shares valued at about $2.19 billion.
argenx SE Stock Down 16.1%
The stock of argenx SE was recently trading at $830.71 as of October 16, 2026. This price is significantly below Wells Fargo's new price target of $1,356, suggesting potential upside if the stock moves towards that target. The stock has been volatile, reflecting broader market trends in the biotechnology sector.
$ARGX price target
argenx SE daily closes and this analyst's $1,356 target. Not advice.
Recent Earnings
In its most recent fiscal year, argenx SE reported a trailing twelve-month revenue of approximately $5.32 billion, along with an EPS of $26.22. The company has demonstrated strong financial health, with a revenue growth rate of 59.3% year-over-year. The next earnings report is expected on October 22, 2026.
Insider Buying and Selling at argenx SE
There were no reported insider transactions for argenx SE during this period.
Analysts Set New Price Targets
On October 14, 2026, Wells Fargo maintained its Overweight rating for argenx SE with a revised price target of $1,356. Earlier, on October 12, 2026, Oppenheimer also maintained its Outperform rating with a target of $1,038, while Evercore ISI Group lowered its target from $1,175 to $1,078 on October 9, 2026. The consensus among analysts suggests a positive outlook for the stock, with varying price targets reflecting differing views on the stock's potential.
About argenx SE
argenx SE, based in Amsterdam, Netherlands, is a biopharmaceutical company that develops therapies for autoimmune diseases. Its key products include VYVGART, which treats generalized Myasthenia Gravis and immune thrombocytopenia, and VYVGART HYTRULO for chronic inflammatory demyelinating polyneuropathy. The company's innovative approaches in biotechnology make it a significant entity in the healthcare sector.
Bottom Line
Investors should keep an eye on argenx SE as it approaches its next earnings report on October 22, 2026. With Wells Fargo's recent price target adjustment, market watchers will be looking for any developments that could drive the stock closer to this target.
Related Filing Alerts
Source: Wells Fargo's rating change on $ARGX (Oct 14, 2026). Written by software, not financial advice. How we make alerts